Stem/progenitor cells, atherosclerosis and cardiovascular regeneration

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 97-104

  Dotsenko, Olena ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Regenerative therapy; Stem cells

Indexed keywords

5' NUCLEOTIDASE; ANGIOPOIETIN RECEPTOR; CD133 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CXCL1 CHEMOKINE; ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 8; NITRIC OXIDE; NOTCH RECEPTOR; STROMAL CELL DERIVED FACTOR 1; THY 1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL HOMING; CELL PROLIFERATION; CELL RENEWAL; CELL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DRUG MECHANISM; EMBRYONIC STEM CELL; HEMATOPOIETIC STEM CELL; HUMAN; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; MYELOID PROGENITOR CELL; MYOBLAST; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TISSUE REGENERATION;

EID: 78249231738     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010097     Document Type: Article

References (83)

1. Seiler C. The human coronary collateral circulation. Heart 2003; 89: 1352-7.
2. Barner HB. Operative treatment of coronary atherosclerosis. Ann Thorac Surg 2008; 85: 1473-1482.
3. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplanta-tion for organ vascularization and regeneration. Nat Med 2003; 9:702-712.
4. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postanatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
5. + bone marrow cells. Blood 2000; 95: 581-585.
6. Sata M. Role of circulating vascular progenitors in angiogenesis, vascular healing and pulmonary hypertension: lessons form animal models. Atherioscler Thromb Vasc Biol 2006; 26: 1008-1014.
7. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci 2001; 98: 10344-10349.
8. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myo-cardial infarction. Arterioscler Thromb Vasc Biol 2008; 28: 208-216.
9. Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myo-cardial infarction: a systematic review. Eur Heart J 2008; 29: 1807-1818.
10. Schächinger V, Erbs S, Elsässer A, et al. Improved clinical out-come after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006; 27: 2775-2783.
11. Kovacic JC, Harvey RP, Dimmeler S. Cardiovascular regenerative medicine: digging in for the long haul. Cell Stem Cell 2007; 1: 628-633.
12. Yoder MC. Defining human endothelial progenitor cells. J Thromb Haemost 2009; 7: 49-52.
13. Sugiyama S, Kugiyama K, Nakamura S, et al. Characterization of smooth muscle-like cells in circulating human peripheral blood. Atherosclerosis 2006; 187: 351-362.
14. Metharom P, Liu C, Wang S, et al. Myeloid lineage of high prolif-erative potential human smooth muscle outgrowth cells circulating in blood and vasculogenic smooth muscle-like cells in vivo. Atherosclerosis 2008; 198: 29-38.
15. Rohde E, Malischnik C, Thaler D, et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006; 24: 357-367.
16. Urbich C, Heeschen C, Aicher A, Dernbach E, Yeiher A, Dimmerler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2006; 108: 2511-2516.
17. Tsai S, Butler J, Rafii S, Liu B, Kent KC. The role of progenitor cells in the development of intimal hyperplasia. J Vasc Surg 2009; 49: 502-510.
18. Hristov M, Zernecke A, Schober A, Weber C. Adult progenitor cells in vascular remodeling during atherosclerosis. Biol Chem 2008; 389: 837-844.
19. Di Stefano R, Felice F, Balbarini A. Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 2009; 15: 1095-106.
20. Torsney E, Mandal K, Halliday A, Jahangiri M, Xu Q. Characterisation of progenitor cells in human atherosclerotic vessels. Atherosclerosis 2007; 191: 259-264.
21. Hristov M, Weber C. Ambivalence of progenitor cells in vascular repair and plaque stability. Curr Opin Lipidol 2008; 19: 491-497.
22. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery dis-ease. Circ Res 2001; 89: E1-E7.
23. Thomas H, Avery P, Ahmed J, Edwards R, Purcell I, Zaman A. Local vessel injury following percutaneous coronary intervention does not promote early mobilization of endothelial progenitor cells in the absence of myocardial necrosis. Heart 2009; 95: 555-558.
24. Wojakowski W, Kucia M, Kazmierski M, Ratajczak M, Tendera M. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanisms? Heart 2008; 94: 27-33.
25. Kopp HG, Ramos CA, Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol 2006; 13: 175-181.
26. Besler C, Doerries C, Giannotti G, Lüscher TF, Landmesser U. Pharmacological approaches to improve endothelial repair mecha-nisms. Expert Rev Cardiovasc Ther 2008; 6: 1071-1082.
27. Zernecke A, Shardarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008; 28: 1897-1907.
28. Yamada T, Kondo T, Numaguchi Y, Tsuzuki M, Matsubara T, Manabe I. Angiotensin II receptor blocker inhibits neointimal hyperplasia through regulation of smooth muscle-like progenitor cells. Arterioscler Thromb Vasc Biol 2007; 27: 2363-2369.
29. van Os R, Kamminga LM, de Haan G. Stem cell assays: something old, something new, something borrowed. Stem Cells 2004; 22: 1181-1190.
30. Pearson T, Greiner DL, Shultz LD. Humanized SCID mouse models for biomedical research. Curr Top Microbiol Immunol 2008; 324: 25-51.
31. Lui KO, Waldmann H, Fairchild PJ. Embryonic stem cells: over-coming the immunological barriers to cell replacement therapy. Curr Stem Cell Res Ther 2009; 4: 70-80.
32. Jaenish R, Young R. Stem cells, the molecular circuitry of pluripo-tency and nuclear reprogramming. Cell 2008; 132: 567-582.
33. Gallacher L, Murdoch B, Wu DM, Karanu FN, Keeney M, Bhatia M. Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood 2000; 95: 2813-2820.
34. Chan RJ, Yoder MC. The multiple facets of hematopoietic stem cells. Curr Neurovasc Res 2004; 1: 197-206.
35. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-2749.
36. Gnecchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol 2009; 482: 281-294.
37. Psaltis PJ, Zannettino A, Worthley SG, Gronthos S. Mesenchymal stromal cells-potential for cardiovascular repair. Stem Cells 2008; 26; 2201-2210.
38. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 93-98.
39. Sanz-Ruiz R, Fernández-Santos E, Domínguez-Muñoa M, et al. Early translation of adipose-derived cell therapy for cardiovascular disease. Cell Transplant 2009; 18: 245-254.
40. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation 2002; 106: 1199-11204.
41. Margariti A, Zeng L, Xu Q. Stem cells, vascular smooth muscle cells and atherosclerosis. Histol Histopathol 2006; 21: 979-985.
42. Tanaka K, Sata M, Hirata Y, Nagai R. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ Res 2003; 93: 783-790.
43. Zoll J, Fontaine V, Gourdy P, et al. Role of human smooth muscle cell progenitors in atherosclerotic plaque development and compo-sition. Cardiovasc Res 2008; 77: 471-480.
44. Sherman W, He KL, Yi GH, et al. Myoblast transfer transfer in ischemic heart failure: effects on rhythm stability. Cell Transplant 2009; 18: 333-341.
45. van Vliet P, Sluijter JP, Doevendans PA, Goumans MJ. Isolation and expansion of resident cardiac progenitor cells. Expert Rev Cardiovasc Ther 2007; 5: 33-43.
46. Aghila RKG, Jayakumar K, Srinivas G, Nair RR, Kartha CC. Isolation of cKit-positive cardiosphere-forming cells from human atrial biopsy. Asian Cardiovasc Thorac Ann 2008; 16: 50-56.
47. Ribatti D. Hemangioblast does exist. Leuk Res 2008; 32: 850-854.
48. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
49. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
50. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343-353.
51. Tendera M, Wojakowski W, Ruzyłło W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009; 30: 1313-1321.
52. Fujiyama S, Amano K, Uehira K, et al. Bone marrow monocytes lineage cells adhere on injured endothelium in a monocytes chemoattractant protein-1-dependent manner and accelerate reen-dothelialization as endothelial progenitor cells. Circ Res 2003; 93: 980-989.
53. Peichev M, Maiyer A, Pereira D, et al. Expression of VEGFR-2 and AC133 be circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952-958.
54. + cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007; 35: 1109-1118.
55. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008; 51: 660-668.
56. Yoder M, Mead L, Prater D, et al. Redefining endothelial progeni-tor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109: 1801-1809.
57. + hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007; 27: 1572-1579.
58. Freundlich B, Avdalovic N. Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J Immunol Methods 1983; 62: 31-7.
59. Liu C, Wang S, Metharom P, Caplice N. Myeloid lineage of human endothelial outgrowth cells circulating in blood and vasculogenic endothelial-like cells in the diseased vessel wall. J Vasc Res 2009; 46: 581-591.
60. Bosco MC, Puppo M, Blengio F, et al. Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. Immunobiology 2008; 213: 733-749.
61. Hristov M, Weber C. Progenitor cell trafficking to the vessel wall. J Thromb Hemost 2009; 7: 31-34.
62. Lataillade JJ, Domenech J, Le Bousse-Kerdiles MC. Stromal cell-derived factor-1 (SDF-1)/CXCR4 couple plays multiple roles on hematopoietic progenitors at the border between the old cytokine and new chemokine worlds: survival, cell cycling and trafficking. Eur Cytokine Net 2004; 15: 177-188.
63. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28: 299-307.
64. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1 alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not suffi-cient to induce homing in the absence of injury. Circulation 2004; 110: 3300-3305.
65. Dentelli P, Rosso A, Balsamo A, et al. C-kit, by interacting with the membrane-bound ligand, recruits endothelail progenitor cells to inflamed endothelium. Blood 2007; 109: 4264-4271.
66. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induc-tion of SDF-1. Nat Med 2004; 10: 858-864.
67. Gallagher KA, Liu ZJ, Xiao M, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007; 117: 1249-1259.
68. Zhang CC, Lodish HF. Cytokins regulating hematopoietic stem cell function. Curr Opin Hematol 2008; 15: 307-311.
69. Dotsenko O, Jahangiri M. Endogenous stem cells in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg 2009 [pii] doi:10.1016/j.ejcts.2009.04.002.
70. Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A. Importance of CXC chemokine receptor 2 in the hom-ing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007; 100: 590-597.
71. Lolmede K, Campana L, Vezzoli M, et al. Inflammatory and alter-natively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1-and MMP-9-dependent pathways. J Leukoc Biol 2009; 85: 779-787.
72. Xu Q, Zhang Z, Davison F, Hu Y. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in apoE-deficient mice. Circ Res 2003; 93: e76-e86.
73. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13: 587-596.
74. George J, Afek A, Abashidze A, et al. Transfer of endothelial pro-genitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterio-scler Thromb Vasc Biol 2005; 25: 2636-2641.
75. Caplice NM, Bunch TJ, Stalboerger PG, et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells admin-istered at marrow transplantation. Proc Natl Acad Sci USA 2003; 100: 4754-4759.
76. Zalewski A, Shi Y, Johnson AG. Diverse origin of intimal cells: smooth muscle cells, myofibroblasts, fibroblasts, and beyond? Circ Res 2002; 91: 652-655.
77. Hu Y, Mayr M, Metzler B, Erdel M, Davison F, Xu Q. Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. Circ Res 2002; 91: e13-e20.
78. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in apoE-deficient mice. J Clin Invest 2004; 113: 1258-1265.
79. Schober A, Knarren S, Lietz M, Lin EA, Weber C. Crucial role of stromal cell-derived factor-1 alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation 2003; 108: 2491-2497.
80. Damås JK, Waehre T, Yndestad A, et al. Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation 2002; 106: 36-42.
81. Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008; 102: 209-217.
82. Karshovska E, Zagorac D, Zernecke A, Weber C, Schober A. A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury. J Thromb Haemost 2008; 6: 1812-1815.
83. Liehn EA, Schober A, Weber C. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque for-mation after arterial injury in ApoE-deficient mice Arterioscler Thromb Vasc Biol 2004; 24: 1891-1896.